Why You Might Be Interested In Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) For Its Upcoming Dividend
Why You Might Be Interested In Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) For Its Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) is about to go ex-dividend in just day or two. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Accordingly, Tianjin Chase Sun PharmaceuticalLtd investors that purchase the stock on or after the 23rd of May will not receive the dividend, which will be paid on the 23rd of May.
一些投資者依靠分紅來增加財富,如果你是這些股息偵探之一,你可能會想知道天津大通藥業有限公司。, Ltd(深圳證券交易所股票代碼:300026)即將在短短一兩天內除息。除息日是記錄日期前的一個工作日,這是股東在公司賬簿上有資格獲得股息的截止日期。除息日很重要,因爲任何股票交易都需要在記錄日期之前結算才有資格獲得股息。因此,在5月23日當天或之後購買股票的天津大通藥業有限公司投資者將不會獲得股息,股息將在5月23日支付。
The company's next dividend payment will be CN¥0.03 per share. Last year, in total, the company distributed CN¥0.03 to shareholders. Calculating the last year's worth of payments shows that Tianjin Chase Sun PharmaceuticalLtd has a trailing yield of 0.8% on the current share price of CN¥3.76. If you buy this business for its dividend, you should have an idea of whether Tianjin Chase Sun PharmaceuticalLtd's dividend is reliable and sustainable. So we need to investigate whether Tianjin Chase Sun PharmaceuticalLtd can afford its dividend, and if the dividend could grow.
該公司的下一次股息將爲每股0.03元人民幣。去年,該公司總共向股東分配了0.03元人民幣。計算去年的付款額顯示,天津大通製藥有限公司的追蹤收益率爲0.8%,而目前的股價爲3.76元人民幣。如果你收購這家企業是爲了分紅,你應該知道天津大通藥業有限公司的股息是否可靠和可持續。因此,我們需要調查天津大通藥業有限公司是否負擔得起股息,以及股息是否可以增加。
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Tianjin Chase Sun PharmaceuticalLtd paid out just 23% of its profit last year, which we think is conservatively low and leaves plenty of margin for unexpected circumstances. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. The good news is it paid out just 15% of its free cash flow in the last year.
股息通常從公司收益中支付。如果一家公司支付的股息超過其利潤,那麼分紅可能是不可持續的。天津大通藥業有限公司去年僅支付了其利潤的23%,我們認爲保守地較低,爲意外情況留下了充足的利潤。然而,在評估股息可持續性方面,現金流通常比利潤更重要,因此我們應始終檢查公司產生的現金是否足以支付股息。好消息是,它去年僅支付了自由現金流的15%。
It's positive to see that Tianjin Chase Sun PharmaceuticalLtd's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
可以肯定的是,天津大通製藥有限公司的股息由利潤和現金流共同支付,因爲這通常表明分紅是可持續的,而較低的派息率通常表明在削減股息之前有更大的安全餘地。
Click here to see how much of its profit Tianjin Chase Sun PharmaceuticalLtd paid out over the last 12 months.
點擊此處查看天津大通藥業有限公司在過去12個月中支付了多少利潤。
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. For this reason, we're glad to see Tianjin Chase Sun PharmaceuticalLtd's earnings per share have risen 13% per annum over the last five years. Earnings per share are growing rapidly and the company is keeping more than half of its earnings within the business; an attractive combination which could suggest the company is focused on reinvesting to grow earnings further. This will make it easier to fund future growth efforts and we think this is an attractive combination - plus the dividend can always be increased later.
增長前景強勁的企業通常是最佳的股息支付者,因爲當每股收益改善時,更容易增加股息。如果收益下降而公司被迫削減股息,投資者可能會看到他們的投資價值化爲烏有。出於這個原因,我們很高興看到天津大通製藥有限公司的每股收益在過去五年中每年增長13%。每股收益快速增長,該公司將一半以上的收益保留在業務中;這種有吸引力的組合可能表明該公司專注於再投資以進一步增加收益。這將使爲未來的增長工作提供資金變得更加容易,我們認爲這是一個有吸引力的組合——而且股息以後可以隨時增加。
Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Tianjin Chase Sun PharmaceuticalLtd has delivered 7.3% dividend growth per year on average over the past 10 years. It's encouraging to see the company lifting dividends while earnings are growing, suggesting at least some corporate interest in rewarding shareholders.
許多投資者將通過評估股息支付在一段時間內發生了多大變化來評估公司的股息表現。在過去的10年中,天津大通藥業有限公司的股息平均每年增長7.3%。令人鼓舞的是,該公司在收益增長的同時提高了股息,這表明至少有一部分企業有興趣獎勵股東。
The Bottom Line
底線
Is Tianjin Chase Sun PharmaceuticalLtd an attractive dividend stock, or better left on the shelf? Tianjin Chase Sun PharmaceuticalLtd has grown its earnings per share while simultaneously reinvesting in the business. Unfortunately it's cut the dividend at least once in the past 10 years, but the conservative payout ratio makes the current dividend look sustainable. Tianjin Chase Sun PharmaceuticalLtd looks solid on this analysis overall, and we'd definitely consider investigating it more closely.
天津大通製藥有限公司是有吸引力的股息股票,還是最好留在架子上?天津大通製藥有限公司增加了每股收益,同時對該業務進行了再投資。不幸的是,它在過去10年中至少削減過一次股息,但是保守的派息率使當前的股息看起來是可持續的。總體而言,天津大通製藥有限公司對這一分析的看法很穩定,我們一定會考慮對其進行更仔細的調查。
While it's tempting to invest in Tianjin Chase Sun PharmaceuticalLtd for the dividends alone, you should always be mindful of the risks involved. Every company has risks, and we've spotted 2 warning signs for Tianjin Chase Sun PharmaceuticalLtd you should know about.
儘管僅憑股息投資天津大通藥業有限公司很誘人,但您應時刻注意所涉及的風險。每家公司都有風險,我們發現了兩個你應該知道的天津大通製藥有限公司的警告信號。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
通常,我們不建議只購買你看到的第一隻股息股票。以下是精選的具有強大股息支付能力的有趣股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。